The Experts below are selected from a list of 198 Experts worldwide ranked by ideXlab platform
M Biour - One of the best experts on this subject based on the ideXlab platform.
-
Etifoxine-induced acute Hepatitis: a case series.
Clinics and Research in Hepatology and Gastroenterology, 2012Co-Authors: Céline Moch, M Biour, Fanny Rocher, Pascale Lainé, Jacqueline Lacotte, Aurore Gouraud, N. Bernard, Jacques Descotes, Thierry VialAbstract:Summary Objective Etifoxine is approved for the treatment of psychosomatic manifestations of anxiety. Several cases of acute Hepatitis have been recently notified to the French pharmacovigilance centres. Our aim was to review all relevant cases of etifoxine Hepatitis. Methods All cases of liver disorders involving etifoxine and reported since November 1995 were extracted from the French pharmacovigilance database. Only cases with suggestive chronological events, no other drug-related or non-drug causes, and sufficient information, were included. Results Of the 30 selected cases, 18 were retained for further analysis. The median duration of treatment before the onset of symptoms was 18 days (11 to 61 days). The results of liver tests evidenced Cytolytic Hepatitis in 15 cases and mixed-type Hepatitis in 3. One patient also exposed to lisinopril/hydrochlorothiazide developed a fulminant Hepatitis that required liver transplantation and six other patients had biological signs of severity. Except for the transplanted patient, 15 patients fully recovered within 3 months, and two clearly improved (further outcome unknown) after etifoxine withdrawal. Conclusion One previously published case and our series confirm that etifoxine can cause acute liver injury with a possibly severe outcome. This adverse effect is not mentioned in the summary of the product characteristics.
-
Cytolytic Hepatitis possibly related to levonorgestrel ethinylestradiol oral contraceptive use 2 case reports
Annals of Pharmacotherapy, 2010Co-Authors: Bouraoui Elouni, Chaker Ben Salem, Michele Zamy, Nathalie Ganne, M Beaugrand, Kamel Bouraoui, M BiourAbstract:This letter to the editor reports on two cases of biopsy-confirmed Cytolytic Hepatitis induced by a levonorgestrel/ethinylestradiol combination oral contraceptive pill.
-
Cytolytic Hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports.
Annals of Pharmacotherapy, 2010Co-Authors: Bouraoui Elouni, Chaker Ben Salem, Michele Zamy, Nathalie Ganne, M Beaugrand, Kamel Bouraoui, M BiourAbstract:This letter to the editor reports on two cases of biopsy-confirmed Cytolytic Hepatitis induced by a levonorgestrel/ethinylestradiol combination oral contraceptive pill.
Bouraoui Elouni - One of the best experts on this subject based on the ideXlab platform.
-
Cytolytic Hepatitis possibly related to levonorgestrel ethinylestradiol oral contraceptive use 2 case reports
Annals of Pharmacotherapy, 2010Co-Authors: Bouraoui Elouni, Chaker Ben Salem, Michele Zamy, Nathalie Ganne, M Beaugrand, Kamel Bouraoui, M BiourAbstract:This letter to the editor reports on two cases of biopsy-confirmed Cytolytic Hepatitis induced by a levonorgestrel/ethinylestradiol combination oral contraceptive pill.
-
Cytolytic Hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports.
Annals of Pharmacotherapy, 2010Co-Authors: Bouraoui Elouni, Chaker Ben Salem, Michele Zamy, Nathalie Ganne, M Beaugrand, Kamel Bouraoui, M BiourAbstract:This letter to the editor reports on two cases of biopsy-confirmed Cytolytic Hepatitis induced by a levonorgestrel/ethinylestradiol combination oral contraceptive pill.
Chantal Loirat - One of the best experts on this subject based on the ideXlab platform.
-
Acute renal failure in a 3-year-old child as part of the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome following Hepatitis A
Pediatric Nephrology, 2008Co-Authors: Arnaud Garnier, El Hachmi Marabet, Theresa Kwon, Michel Peuchmaur, Olivia Mourier, Véronique Baudouin, Georges Deschênes, Chantal LoiratAbstract:We report on a 3-year-old Melanesian girl admitted for acute renal failure following subfulminant Hepatitis A virus infection. While the child was slowly recovering from severe Cytolytic Hepatitis, she presented 8 weeks of protracted fever and major eosinophilia (30,000/μl); thereafter, acute renal failure (serum creatinine 295 μmol/l) occurred. Renal histology displayed diffuse eosinophilic infiltrate, with severe acute tubulointerstitial lesions associated with mild glomerular endocapillary proliferation and eosinophilic infiltrate, suggesting an immunoallergic mechanism. The child had received cefixime and cotrimoxazole 3 weeks prior to hospitalisation for the Hepatitis A virus infection. The final diagnosis was of the syndrome drug reaction with eosinophilia and systemic symptoms or DRESS, induced by cefixime or cotrimoxazole and possibly triggered by the Hepatitis A virus infection.
Ablaye Leye - One of the best experts on this subject based on the ideXlab platform.
-
PURPURA THROMBOPENIQUE, MYOSITE ET HEPATITE CYTOLYTIQUE : UNE ASSOCIATION RARE D'INCIDENTS LIES A L'ATORVASTATINE. Thrombocytopenia purpura, myositis and cytolitic Hepatitis: a rare association of adverse events associated with atorvastatin.
2020Co-Authors: Touré P S, Léye Y M, M. Diop, Ablaye Leye, Souleymane Touré, Yakham Mohamed, Madoky Maguette, Mamadou Mourtalla, KaAbstract:Statins are generally well tolerated drugs. Potentially life-threatening adverse events can occur. We report a case of a 70-year-old woman with high blood pressure with hypercholesterolemia treated by atorvastatin. Two weeks after introduction of this new drug the patient developed muscular weakness of all four limbs with myalgia, purpura and upper limbs and abdomen. Biology revealed severe thrombocytopenia, myolysis and Cytolytic Hepatitis. The cessation of atorvastatin resulted in a favorable in twenty days. This suggests the drug-induced abnormalities found. The literature data confirm the rarity of this association. The severity of some side effects of statins should remain in the minds of prescribers. Keywords : atorvastatin, purpura, myositis, cytolysis, side effects.
-
Thrombocytopenia purpura, myositis and cytolitic Hepatitis: a rare association linked with atorvastatin
Le Mali medical, 2020Co-Authors: P.-s. Toure, Ablaye Leye, Yakham Mohamed Leye, M. M. Diop, S. El Fajri, Mamadou Mourtalla KaAbstract:: Statins are generally well tolerated molecules. However, some cases have seen potentially lifethreatening consequences. We report a case of a 70-year-old woman with high blood pressure who was treating hypercholesterolemia by atorvastatin. Two weeks after beginning this new treatment, the patient developed muscular weakness in all four limbs with myalgias; and a purpura in the upper limbs and abdomen. A biological study revealed the presence of severe thrombocytopenia, myolysis and Cytolytic Hepatitis. Stopping the atorvastatin intake resulted in an improved situation within twenty days. This suggests that the medical anomalies found in the patient were drug-induced. The literature confirms the rarity of this association. The severity of some side effects of statins should remain in the minds of medicine prescribers.
-
Carbimazole Drug-Induced Hepatitis during Treatment of Graves’ Disease: About Four Cases at Dakar Teaching Hospital
Open Journal of Internal Medicine, 2017Co-Authors: Ablaye Leye, Yakham Mohamed Leye, Michel Assane Ndour, Nafy Ndiaye Sarr, Ngoné Diaba Diack, Dominique Emmanuel FayeAbstract:Introduction: Mostly reported common side effects of carbimazole are cutaneous allergies and severe agranulocytosis. However, hepatotoxicity is rarely described. Thus, we report four observations of carbimazole drug-induced Hepatitis during the treatment of Graves’ disease, which imputability is likely and probably an immuno-allergic mechanism. Observations: They were four women whose average age was 43 years, with extreme ages of 32 and 54. Patients were monitored and treated with carbimazole in doses contained between 40 mg and 60 mg per day. Clinical manifestations of liver injury were mainly dominated by cholestatic jaundice, found in 100% of our patients. A painful sensitivity of the right hypochondrium was concomitant with jaundice for two patients. The jaundice time to onset after the beginning of treatment with carbimazole varies between 1 month and 6 months. They all had acute Hepatitis. The biological assays used to determine the type of liver injury showed, in all cases, a mixed, cholestatic and Cytolytic Hepatitis. Therapeutically, in all patients, carbimazole was stopped as soon as the suspicion of its incrimination in the occurrence of liver damage was set up. They all had a substitution of carbimazole with benzylthiouracil. Evolution was favorable for all patients, after therapeutic substitution. It was marked by disappearance of jaundice and normalization of the liver biological parameters within a maximum delay of two months after stopping carbimazole use. Conclusion: Treatment with synthetic antithyroid drugs, particularly carbimazole that is most widely used in our regions, requires clinical and biological monitoring. This surveillance, which is often difficult in Africa because of the limited economic resources, can lead to the occurrence of side effects such as potentially serious drug-induced Hepatitis, but which has been favorable in our observations.
P.-s. Toure - One of the best experts on this subject based on the ideXlab platform.
-
Thrombocytopenia purpura, myositis and cytolitic Hepatitis: a rare association linked with atorvastatin
Le Mali medical, 2020Co-Authors: P.-s. Toure, Ablaye Leye, Yakham Mohamed Leye, M. M. Diop, S. El Fajri, Mamadou Mourtalla KaAbstract:: Statins are generally well tolerated molecules. However, some cases have seen potentially lifethreatening consequences. We report a case of a 70-year-old woman with high blood pressure who was treating hypercholesterolemia by atorvastatin. Two weeks after beginning this new treatment, the patient developed muscular weakness in all four limbs with myalgias; and a purpura in the upper limbs and abdomen. A biological study revealed the presence of severe thrombocytopenia, myolysis and Cytolytic Hepatitis. Stopping the atorvastatin intake resulted in an improved situation within twenty days. This suggests that the medical anomalies found in the patient were drug-induced. The literature confirms the rarity of this association. The severity of some side effects of statins should remain in the minds of medicine prescribers.
-
Purpura thrombopénique, myosite et hépatite cytolytique : une association d’incidents liés à l’atorvastatine
2012Co-Authors: P.-s. ToureAbstract:Statins are generally well tolerated drugs. Potentially life-threatening adverse events can occur. We report a case of a 70-year-old woman with high blood pressure with hypercholesterolemia treated by atorvastatin. Two weeks after introduction of this new drug the patient developed muscular weakness of all four limbs with myalgia, purpura and upper limbs and abdomen. Biology revealed severe thrombocytopenia, myolysis and Cytolytic Hepatitis. The cessation of atorvastatin resulted in a favorable in twenty days. This suggests the drug-induced abnormalities found. The literature data confirm the rarity of this association. The severity of some side effects of statins should remain in the minds of prescribers.
